Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-04-19
2011-04-19
Stoica, Elly-Gerald (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S361000
Reexamination Certificate
active
07928073
ABSTRACT:
This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4.
REFERENCES:
patent: 5596072 (1997-01-01), Culpepper et al.
patent: 5710023 (1998-01-01), Collins et al.
patent: 6911530 (2005-06-01), Willson et al.
Hilton et al PNAS 1996, vol. 93, pp. 497-501.
Lefort et al, IL-13 and IL-4 share signal transduction elements as well as receptor components in TF-1 cells, FEBS Letters, vol. 336, No. 203, Jun. 12, 1995, pp. 122-126.
Vita et al., Characterization and Comparison of the Interleukin 13 Receptor with the Interleukin 4 Receptor on Several Cell Types, J. of Bio. Chem., vol. 270, No. 8, Feb. 24, 1995, pp. 3512-3517.
Obiri et al., Receptor for Interleukin 13, J. of Bio. Chem., vol. 270, No. 15, Apr. 14, 1995, pp. 8797-8804.
Zurawski et al., The Primary Binding Subunit of the Human Interleukin-4 Receptor Is Also a Component of the Interleukin-13 Receptor, J. of Bio. Chem., vol. 270, No. 23, Jun. 9, 1995.
Aman et al., cDNA Cloning and Characterization of the Human Interleukin 13 Receptor alpha Chain, J. of Bio. Chem., vol. 271, No. 46, Nov. 15, 1996, pp. 29265-29270.
Caput et al., Cloning and Characterization of a Specific Interleukin (IL-13) Binding Protein Structurally Related to the IL-5 Receptor alpha Chain, J. of Bio. Chem., vol. 271, No. 208, Jul. 12, 1996, pp. 16921-16926.
Callard et al., IL-4 and IL-13 receptors: are they one and the same?, Immunology Today, vol. 17, No. 3, Mar. 1996, pp. 108-110.
Wills-Karp, Interleukin-13: Central Mediator of Allergic Asthama, Immunology Today, vol. 17, No. 2, Mar. 1996.
Caput Daniel
Ferrara Pascual
Laurent Patrick
Vita Natalio
Fontenot J. Darrell
Sanofi-Aventis
Stoica Elly-Gerald
LandOfFree
Purified polypeptides having IL-13 receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purified polypeptides having IL-13 receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified polypeptides having IL-13 receptor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694600